<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - FENTANYL</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>FENTANYL</h1>

        <p><a href="../drugClass/PHP34573.html">OPIOIDS</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Chronic intractable pain not currently treated with a strong opioid analgesic</span>,
            </h4>
            <p class="specificity"><span class="route">By transdermal application</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 12 micrograms/hour every 72 hours, alternatively initially 25 micrograms/hour every 72 hours, when starting, evaluation of the analgesic effect should not be made before the system has been worn for 24 hours (to allow for the gradual increase in plasma-fentanyl concentration)&#8212;previous analgesic therapy should be phased out gradually from time of first patch application, dose should be adjusted at 48&#8211;72 hour intervals in steps of 12&#8211;25 micrograms/hour if necessary, more than one patch may be used at a time (but applied at the same time to avoid confusion)&#8212;consider additional or alternative analgesic therapy if dose required exceeds 300 micrograms/hour (important: it takes 17 hours or more for the plasma-fentanyl concentration to decrease by 50%&#8212; replacement opioid therapy should be initiated at a low dose and increased gradually).</li>
              <li class="dose child"><strong>For children 16&#8211;17 years</strong><br/>
                Initially 12 micrograms/hour every 72 hours, alternatively initially 25 micrograms/hour every 72 hours, when starting, evaluation of the analgesic effect should not be made before the system has been worn for 24 hours (to allow for the gradual increase in plasma-fentanyl concentration)&#8212;previous analgesic therapy should be phased out gradually from time of first patch application, dose should be adjusted at 48&#8211;72 hour intervals in steps of 12&#8211;25 micrograms/hour if necessary, more than one patch may be used at a time (but applied at the same time to avoid confusion)&#8212;consider additional or alternative analgesic therapy if dose required exceeds 300 micrograms/hour (important: it takes 17 hours or more for the plasma-fentanyl concentration to decrease by 50%&#8212; replacement opioid therapy should be initiated at a low dose and increased gradually).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Chronic intractable pain currently treated with a strong opioid analgesic</span>,
            </h4>
            <p class="specificity"><span class="route">By transdermal application</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initial dose based on previous 24-hour opioid requirement (consult product literature), for evaluating analgesic efficacy and dose increments, see under Chronic intractable pain not currently treated with a strong opioid analgesic, for conversion from long term oral morphine to transdermal fentanyl, see Pain management with opioids under Prescribing in palliative care.</li>
              <li class="dose child"><strong>For children 2&#8211;17 years</strong><br/>
                Initial dose based on previous 24-hour opioid requirement (consult product literature), for evaluating analgesic efficacy and dose increments, see under Chronic intractable pain not currently treated with a strong opioid analgesic, for conversion from long term oral morphine to transdermal fentanyl, see Pain management with opioids under Prescribing in palliative care.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Spontaneous respiration: analgesia and enhancement of anaesthesia, during operation</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 50&#8211;100 micrograms (max. per dose 200 micrograms), dose maximum on specialist advice, then 25&#8211;50 micrograms as required.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                3&#8211;4.8 micrograms/kg/hour, adjusted according to response.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Assisted ventilation: analgesia and enhancement of anaesthesia during operation</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 300&#8211;3500 micrograms, then 100&#8211;200 micrograms as required.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 10 micrograms/kg, dose to be given over 10 minutes, then 6 micrograms/kg/hour, adjusted according to response, may require up to 180 micrograms/kg/hour during cardiac surgery.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Assisted ventilation: analgesia and respiratory depression in intensive care</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 300&#8211;3500 micrograms, then 100&#8211;200 micrograms as required.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 10 micrograms/kg, dose to be given over 10 minutes, then 6 micrograms/kg/hour, adjusted according to response, may require up to 180 micrograms/kg/hour during cardiac surgery.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Breakthrough pain in patients receiving opioid therapy for chronic cancer pain</span>,
            </h4>
            <p class="specificity"><span class="route">By buccal administration using buccal films</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 200 micrograms, dose to be given over 15 minutes, then (by buccal administration) 200 micrograms after 15 minutes if required, no more than 2 dose units for each pain episode; if adequate pain relief not achieved with 1 dose unit for consecutive breakthrough pain episodes, increase the strength of the dose unit until adequate pain relief achieved with 4 lozenges or less daily, if more than 4 episodes of breakthrough pain each day, adjust background analgesia.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 200 micrograms, adjusted according to response, consult product literature for information on dose adjustments, maximum 1.2 mg per episode of breakthrough pain; leave at least 4 hours between treatment of episodes of breakthrough pain, if more than 4 episodes of breakthrough pain each day occur on more than 4 consecutive days, adjust background analgesia.</li>
              <li class="dose child"><strong>For children 16&#8211;17 years</strong><br/>
                Initially 200 micrograms, dose to be given over 15 minutes, then (by buccal administration) 200 micrograms after 15 minutes if required, no more than 2 dose units for each pain episode; if adequate pain relief not achieved with 1 dose unit for consecutive breakthrough pain episodes, increase the strength of the dose unit until adequate pain relief achieved with 4 lozenges or less daily, if more than 4 episodes of breakthrough pain each day, adjust background analgesia.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>Fentanyl films are <b>not bioequivalent</b> to other fentanyl preparations.</p><p>Fentanyl preparations for the treatment of breakthrough pain are not interchangeable; if patients are switched from another fentanyl-containing preparation, a new dose titration is required.</p>
            </section>
        
            <section class="extremesOfBodyWeight">
                <h3>Doses at extremes of body-weight</h3>
              <p>To avoid excessive dosage in obese patients, dose may need to be calculated on the basis of ideal bodyweight.</p>
            </section>
        
        
      </section>





      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.</p>
            </section>
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain, aesthenia, anorexia, anxiety, appetite changes, application-site reactions, diarrhoea, dyspepsia, dyspnoea, gastro-oesophageal reflux disease, hypertension, myoclonus, paraesthesia, pharyngitis, rhinitis, stomatitis, tremor, vasodilation,
              </p>
              <p>
                <strong>uncommon:</strong> Amnesia, arthralgia, blood disorders, chills, depressed level of consciousness, dysgeusia, flatulence, hypoventilation, ileus, impaired concentration, impaired coordination, loss of consciousness, malaise, parosmia, pyrexia, seizures, speech disorder, thirst, thrombocytopenia,
              </p>
              <p>
                <strong>rare:</strong> Hiccups,
              </p>
              <p>
                <strong>veryRare:</strong> Apnoea, arrhythmia, ataxia, bladder pain, delusions, haemoptysis,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> myoclonic movements,
              </p>
              <p>
                <strong>uncommon:</strong> laryngospasm,
              </p>
              <p>
                <strong>rare:</strong> asystole, insomnia,
              </p>
        
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">transdermal</ph> use</h3>
                <p class="title">Fever or external heat</p>
              <p>Monitor patients using patches for increased side-effects if fever present (increased absorption possible); avoid exposing application site to external heat, for example a hot bath or sauna (may also increase absorption).</p>
            </section>
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
                <p class="title">Muscle rigidity</p>
              <p>Fentanyl can cause muscle rigidity, particularly of the chest wall or jaw; this can be managed by the use of neuromuscular blocking drugs.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">transdermal</ph> use</h3>
              <p>For <i>patches</i>, apply to dry, non-irritated, non-irradiated, non-hairy skin on torso or upper arm, removing after 72&#8239;hours and siting replacement patch on a different area (avoid using the same area for several days).</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>For <i>intravenous infusion</i>, injection solution may be diluted in Glucose 5% or Sodium Chloride 0.9%.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For <i>intravenous infusion</i>(<i>Sublimaze</i>), give continuously or intermittently in Glucose 5% or Sodium Chloride 0.9%.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">buccal</ph> use in adults</h3>
              <p>For buccal films, moisten mouth, place film on inner lining of cheek (pink side to cheek), hold for at least 5&#8239;seconds until it sticks, and leave to dissolve (15&#8211;30 minutes); if more than 1 film required do not overlap, but use another area of the mouth. Avoid liquids for 5&#8239;minutes after application; avoid food until the film has dissolved.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">buccal</ph> use</h3>
              <p>Patients should be advised to place the lozenge in the mouth against the cheek and move it around the mouth using the applicator; each lozenge should be sucked over a 15&#8239;minute period. In patients with a dry mouth, water may be used to moisten the buccal mucosa. Patients with diabetes should be advised each lozenge contains approximately 2&#8239;g glucose.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <h3 class="specificity">With <ph outputclass="route">transdermal</ph> use</h3>
              <p>Patients and carers should be informed about safe use, including correct administration and disposal, strict adherence to dosage instructions, and the symptoms and signs of opioid overdosage.</p><p>Patches should be removed immediately in case of breathing difficulties, marked drowsiness, confusion, dizziness, or impaired speech, and patients and carers should seek prompt medical attention.</p>
            </section>
            <section class="generalPatientAdvice">
              <h3 class="specificity">With <ph outputclass="route">buccal</ph> use in adults</h3>
              <p>Patients or carers should be given advice on how to administer fentanyl buccal films or fentanyl lozenges.</p>
            </section>
            <section class="generalPatientAdvice">
              <h3 class="specificity">With <ph outputclass="route">intranasal</ph> use in adults</h3>
              <p>Patients or carers should be given advice on how to administer fentanyl nasal spray.</p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Fentanyl lozenges for pain</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/fentanyl-lozenges-for-pain">www.medicinesforchildren.org.uk/fentanyl-lozenges-for-pain</xref>
            </p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Fentanyl patches for pain</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/fentanyl-patches-for-pain">www.medicinesforchildren.org.uk/fentanyl-patches-for-pain</xref>
            </p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Cerebral tumour
          </li>
          <li>
            diabetes mellitus (with <i>Actiq</i> <tm tmtype="reg"/> lozenges)
          </li>
          <li>
            impaired consciousness
          </li>
        </ul>
        <ul>
          <li>
              <strong>With buccal use:</strong>
            mucositis&#8212;absorption from oral preparations may be increased, caution during dose titration in adults
          </li>
        </ul>
        <ul>
          <li>
              <strong>With <ph outputclass="route">transdermal</ph> use:</strong>
            <p>Transdermal fentanyl patches) are not suitable for acute pain or in those patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose.</p><p>Risk of fatal respiratory depression, particularly in patients not previously treated with a strong opioid analgesic; manufacturer recommends use only in opioid tolerant patients.</p>
          </li>
          <li>
              <strong>With <ph outputclass="route">intravenous</ph> use:</strong>
            <p>Repeated intra-operative doses should be given with care since the resulting respiratory depression can persist postoperatively and occasionally it may become apparent for the first time postoperatively when monitoring of the patient might be less intensive.</p>
          </li>
        </ul>
      </section>



      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>Not licensed for use in children under 2 years; infusion not licensed for use in children under 12 years.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">With <ph outputclass="route">transdermal</ph> use</h3>
              <p>Prescriptions for fentanyl patches can be written to show the strength in terms of the release rate and it is acceptable to write <i>'Fentanyl 25 patches</i>&#8216; to prescribe patches that release fentanyl 25&#8239;micrograms per hour. The dosage should be expressed in terms of the interval between applying a patch and replacing it with a new one, e.g. <i>'one patch to be applied every 72 hours'</i>. The total quantity of patches to be supplied should be written in words and figures.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of FENTANYL</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            solution for injection,
            solution for infusion,
            infusion,

            <div id="PHP77128"><a href="../medicinalForm/PHP77128.html" data-target="#PHP77128" data-action="load">Sublingual tablet</a></div>
            <div id="PHP77070"><a href="../medicinalForm/PHP77070.html" data-target="#PHP77070" data-action="load">Buccal tablet</a></div>
            <div id="PHP77107"><a href="../medicinalForm/PHP77107.html" data-target="#PHP77107" data-action="load">Buccal film</a></div>
            <div id="PHP77055"><a href="../medicinalForm/PHP77055.html" data-target="#PHP77055" data-action="load">Lozenge</a></div>
            <div id="PHP77090"><a href="../medicinalForm/PHP77090.html" data-target="#PHP77090" data-action="load">Solution for injection</a></div>
            <div id="PHP77100"><a href="../medicinalForm/PHP77100.html" data-target="#PHP77100" data-action="load">Solution for infusion</a></div>
            <div id="PHP77115"><a href="../medicinalForm/PHP77115.html" data-target="#PHP77115" data-action="load">Transdermal patch</a></div>
            <div id="PHP77076"><a href="../medicinalForm/PHP77076.html" data-target="#PHP77076" data-action="load">Spray</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
